1,118 reports of this reaction
1.9% of all RABEPRAZOLE SODIUM reports
#11 most reported adverse reaction
TUBULOINTERSTITIAL NEPHRITIS is the #11 most commonly reported adverse reaction for RABEPRAZOLE SODIUM, manufactured by Waylis Therapeutics LLC. There are 1,118 FDA adverse event reports linking RABEPRAZOLE SODIUM to TUBULOINTERSTITIAL NEPHRITIS. This represents approximately 1.9% of all 58,263 adverse event reports for this drug.
Patients taking RABEPRAZOLE SODIUM who experience tubulointerstitial nephritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TUBULOINTERSTITIAL NEPHRITIS is a less commonly reported adverse event for RABEPRAZOLE SODIUM, but still significant enough to appear in the safety profile.
In addition to tubulointerstitial nephritis, the following adverse reactions have been reported for RABEPRAZOLE SODIUM:
The following drugs have also been linked to tubulointerstitial nephritis in FDA adverse event reports:
TUBULOINTERSTITIAL NEPHRITIS has been reported as an adverse event in 1,118 FDA reports for RABEPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
TUBULOINTERSTITIAL NEPHRITIS accounts for approximately 1.9% of all adverse event reports for RABEPRAZOLE SODIUM, making it a notable side effect.
If you experience tubulointerstitial nephritis while taking RABEPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.